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SMN1 is the gene responsible for Spinal Muscular Atrophy (SMA), a devastating neuromuscular disease 
characterized by progressive and selective degeneration of lower motor neurons (MNs), leading to muscle 
atrophy and death of patients. SMA has been extensively studied, but the molecular mechanisms leading to 
MNs degeneration are still unknown. Therefore, animal SMA models are crucial to understand the 
pathogenesis of the disease and the functions played by SMN. In C.elegans, as in all models, SMN ortholog 
(smn-1) full depletion causes strong larval lethality and impaired locomotion. We overcame smn-1 KO 
pleiotropic effects by silencing smn-1 only in 19 MNs (Gallotta et al., HMG 2016) and we observed an age-
dependent degeneration and neuronal death that mimic the key features of SMA pathology. Hence, we used 
our SMA model as a tool to identify new neuroprotective modifiers, genetically interacting with smn-1 in the 
MNs. By RNA sequencing of SMA patients-derived iPSC we identified SYNCRIP, a heterogeneous nuclear 
ribonucleoprotein, as a new modifier of SMN function. SYNCRIP, similarly to SMN1, is part of the spliceosome 
and is involved in pre-mRNA processing and transport. SYNCRIP homolog in C. elegans is hrp-2, a gene 
expressed in all tissues, including MNs. We demonstrated that HRP-2/SYNCRIP overexpression in neurons is 
able to partially rescue, in vivo, the neurodegeneration, the neuronal death and the defects in locomotion 
observed in our model (Rizzo et al., Brain under revision). Our results strongly suggest SYNCRIP as a new 
potential target for innovative combinatorial therapeutic approaches for SMA.  
 
